Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies

Immunoglobulin G replacement therapy prevents infections in patients with antibody deficiencies. Subcutaneous immunoglobulin (SCIg) has typically been administered via infusion pump, but the manual push technique offers a simple, convenient alternative method. The manual push technique is efficaciou...

Full description

Saved in:
Bibliographic Details
Main Author: Alex Richter
Format: Article
Language:English
Published: Taylor & Francis Group 2025-06-01
Series:Immunological Medicine
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/25785826.2025.2515333
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849705250326315008
author Alex Richter
author_facet Alex Richter
author_sort Alex Richter
collection DOAJ
description Immunoglobulin G replacement therapy prevents infections in patients with antibody deficiencies. Subcutaneous immunoglobulin (SCIg) has typically been administered via infusion pump, but the manual push technique offers a simple, convenient alternative method. The manual push technique is efficacious, well tolerated, quick to administer, offers increased dosing flexibility, and does not rely on a pump. Having various administration options available to patients provides greater treatment satisfaction and feelings of self-empowerment, which may improve compliance. Currently available literature published before 10 February 2022, that reported patient and healthcare professional experience with SCIg administered via manual push, were reviewed. Literature searches were performed using PubMed, Google and ClinicalTrials.gov using key words ‘manual push’, ‘rapid push’, ‘immunoglobulin’, ‘subcutaneous immunoglobulin’, ‘SCIg’, and ‘primary immunodeficiency’. Real-world evidence demonstrates all delivery techniques provide similar efficacy, so treatment administration becomes about patient preference, hospital resources, cost-effectiveness/recovery and clinician attitude. To establish newer administration modalities such as manual push or prefilled syringes, there needs to be patient awareness of these options, then education and finally confidence in recommending these options. Adoption of newer administration modalities will help ensure patients receive the widest range of choice, thus improving compliance and their risk of recurrent and severe infection.
format Article
id doaj-art-8cddeeee271f43afb9f2d7b46c878eee
institution DOAJ
issn 2578-5826
language English
publishDate 2025-06-01
publisher Taylor & Francis Group
record_format Article
series Immunological Medicine
spelling doaj-art-8cddeeee271f43afb9f2d7b46c878eee2025-08-20T03:16:31ZengTaylor & Francis GroupImmunological Medicine2578-58262025-06-0111210.1080/25785826.2025.2515333Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficienciesAlex Richter0School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UKImmunoglobulin G replacement therapy prevents infections in patients with antibody deficiencies. Subcutaneous immunoglobulin (SCIg) has typically been administered via infusion pump, but the manual push technique offers a simple, convenient alternative method. The manual push technique is efficacious, well tolerated, quick to administer, offers increased dosing flexibility, and does not rely on a pump. Having various administration options available to patients provides greater treatment satisfaction and feelings of self-empowerment, which may improve compliance. Currently available literature published before 10 February 2022, that reported patient and healthcare professional experience with SCIg administered via manual push, were reviewed. Literature searches were performed using PubMed, Google and ClinicalTrials.gov using key words ‘manual push’, ‘rapid push’, ‘immunoglobulin’, ‘subcutaneous immunoglobulin’, ‘SCIg’, and ‘primary immunodeficiency’. Real-world evidence demonstrates all delivery techniques provide similar efficacy, so treatment administration becomes about patient preference, hospital resources, cost-effectiveness/recovery and clinician attitude. To establish newer administration modalities such as manual push or prefilled syringes, there needs to be patient awareness of these options, then education and finally confidence in recommending these options. Adoption of newer administration modalities will help ensure patients receive the widest range of choice, thus improving compliance and their risk of recurrent and severe infection.https://www.tandfonline.com/doi/10.1080/25785826.2025.2515333Home-based therapyimmunoglobulin replacement therapyindividualized dosingmanual pushprimary immunodeficiency (PID)rapid push
spellingShingle Alex Richter
Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies
Immunological Medicine
Home-based therapy
immunoglobulin replacement therapy
individualized dosing
manual push
primary immunodeficiency (PID)
rapid push
title Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies
title_full Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies
title_fullStr Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies
title_full_unstemmed Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies
title_short Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies
title_sort current experience with manual push subcutaneous immunoglobulin scig in patients with immune deficiencies
topic Home-based therapy
immunoglobulin replacement therapy
individualized dosing
manual push
primary immunodeficiency (PID)
rapid push
url https://www.tandfonline.com/doi/10.1080/25785826.2025.2515333
work_keys_str_mv AT alexrichter currentexperiencewithmanualpushsubcutaneousimmunoglobulinsciginpatientswithimmunedeficiencies